What did Purdue Pharma L.P. admit in 2020, and how was it sentenced?

analysisAccording to the debtors' Disclosure Statement of 1 July 2025, the Department of Justice had investigated them since at least June 2016: Purdue Pharma L.P. received a U.S. Attorney's subpoena about OxyContin marketing in summer 2016 and, from December 2017, further subpoenas and requests from other U.S. Attorney's Offices and DOJ components about its opioids, monitoring programs, payments to professionals and marketing, and it produced more than 13 million documents (over 100 million pages). On 30 July 2020 the United States filed a proof of claim in the bankruptcy asserting non-dischargeable civil claims under the False Claims Act and other laws and estimating single damages of $2.8 billion or more, plus trebling and penalties. On information and belief, and reserving the right to amend while its investigation continued, it alleged that from 2010 to 2018 Purdue detailed prescribers nationwide, including some it knew were facilitating medically unnecessary prescriptions, paid kickbacks to prescribers through advisor and speaker programs (over $3 million for advising and over $10 million for speaking from 2013 to 2018), paid the records vendor Practice Fusion for a 'Pain CDS' alert live from about 6 July 2016 to spring 2019, and from October 2015 paid three specialty pharmacies over $137,000 to fill OxyContin prescriptions other pharmacies had rejected. In the civil settlement of October 2020 Purdue gave the United States an allowed general unsecured claim of $2.8 billion, and DOJ stated that, beyond Purdue's criminal admissions, the civil claims were allegations only, with no determination of liability. ^{1 2 3}

analysisOn 21 October 2020 DOJ announced a global resolution with Purdue Pharma LP, subject to approval by the bankruptcy court. The company would plead guilty in federal court in New Jersey to a three-count felony information, with a criminal fine of $3.544 billion and $2 billion in criminal forfeiture, and it also agreed to a $2.8 billion civil settlement of its False Claims Act liability. Of the forfeiture the company would pay $225 million on the effective date of the bankruptcy, and DOJ was willing to credit up to $1.775 billion for value conferred on State and local governments, under a condition of the resolution that the company cease to operate in its current form and emerge from bankruptcy as a public benefit company owned by a trust or similar entity for the benefit of the American public. DOJ stated that the resolutions did not include a criminal release for any individual, including members of the Sackler family, and that no company executive or employee received a civil release. ¹

analysisThe Information was filed on 24 November 2020 in the U.S. District Court for the District of New Jersey (Criminal No. 20-1028 (MCA), Judge Madeline Cox Arleo) against Purdue Pharma L.P. alone, the company having waived indictment. Count One charged a conspiracy from about 11 May 2007 to 9 February 2018 to defraud the United States by impeding the DEA's ability to prevent diversion of controlled substances and to aid and abet the misbranding of prescription drugs held for sale without valid prescriptions; Count Two a conspiracy to violate the Anti-Kickback Statute from at least June 2009 to about February 2018 by paying prescribers kickbacks disguised as speaker fees; Count Three a further Anti-Kickback conspiracy, with Practice Fusion and others, from no later than about March 2016 to at least November 2016, to pay Practice Fusion in return for arranging or recommending the company's opioids. The forfeiture allegation put the value of the misbranded and unapproved drugs at $2,000,000,000 and also sought the proceeds of Counts Two and Three, with a substitute-assets clause. The company pleaded guilty to the three counts, its board chairman Steve Miller having stated in its release of 21 October 2020 that 'Purdue deeply regrets and accepts responsibility for the misconduct detailed by the Department of Justice in the agreed statement of facts'. On 28 April 2026 the court sentenced it to a $3.544 billion fine, assessed in the bankruptcy, and ordered the $2 billion forfeiture, up to $1.775 billion of it to be credited for value conferred on state, local and tribal governments if Purdue ceases to operate in its current form and emerges as a public benefit company or similar entity; the plan confirmed on 18 November 2025 carries both as DOJ claims and finds that the value conferred exceeds $1.775 billion. ^{1 2 3 4}

analysisDOJ's announcement of 21 October 2020 summarised what Purdue would admit as part of the plea: that from May 2007 through at least March 2017 it conspired to defraud the United States by impeding the DEA, claiming an effective anti-diversion program while marketing to more than 100 providers it had good reason to believe were diverting opioids and reporting misleading prescription data to raise its manufacturing quotas, a conspiracy that also involved aiding and abetting violations of the Food, Drug, and Cosmetic Act; that between June 2009 and March 2017 it paid two doctors through its speaker program to induce more prescriptions; and that from about April to December 2016 it paid Practice Fusion for referring, recommending and arranging for the ordering of OxyContin, Butrans and Hysingla. The District Court later recorded that in Schedule A to the plea agreement, to whose facts the corporation stipulated, Purdue admitted offering payments to induce prescriptions, offering prescription savings cards and failing to maintain effective controls against diversion, including not telling the DEA that providers flagged for abuse filled over 1.4 million OxyContin prescriptions; the court noted that the Sacklers do not concede the truth of Purdue's admissions. ^{1 2}

analysisThe Second Circuit's opinion of 30 May 2023 described the plea agreement's terms: DOJ agreed not to 'initiate any further criminal charges against Purdue'; Purdue agreed to a $2 billion forfeiture judgment with 'superpriority' in any liquidation; DOJ would release $1.775 billion of that claim if a future plan created an abatement trust for the public benefit and a document repository; and the agreement released Purdue from further civil or administrative monetary claims by the government for the covered conduct but expressly did not release criminal liability. The debtors' Disclosure Statement of July 2025 adds that Purdue Pharma L.P. would be excluded from federal healthcare programs if the plea agreement was accepted and it was convicted, an exclusion the resolution anticipated by having a public benefit company or similar entity continue selling the debtors' medicines. ^{3 4 5}

analysisPurdue Pharma L.P. pleaded guilty on 24 November 2020 to all three counts (USA v. Purdue Pharma L.P., No. 2:20-cr-01028, D.N.J.); the plea was the company's, and no individual was charged in the case. The District Court for the Southern District of New York later described it as a plea in which 'the company (though not the people through whom the company acted) admitted to substantial deliberate wrongful conduct'; on announcing the resolution the company's chairman had said, as quoted above, that Purdue 'deeply regrets and accepts responsibility' for the misconduct detailed in the agreed statement of facts. On 28 April 2026 the company was sentenced in federal court in Newark, New Jersey, to criminal penalties of over $5 billion: a criminal fine of $3.544 billion, to be assessed in the bankruptcy, and $2 billion in criminal forfeiture, against which DOJ will credit up to $1.775 billion for value conferred on state, local and tribal governments if Purdue ceases to operate in its current form and emerges as a public benefit company or similar entity; Purdue must also host a public repository of documents relating to the charges. The Bankruptcy Court's order of 18 November 2025 confirming the Eighteenth Amended Plan carries the DOJ civil claim of $2.8 billion, the criminal fine claim of $3.544 billion and the forfeiture judgment claim of $2 billion, each as defined in the court's earlier order approving the debtors' settlements with the United States, together with a forfeiture credit capped at $1.775 billion and a $225 million cash forfeiture payment by Purdue Pharma L.P. to the United States Marshals; the order finds that the value conferred on non-federal governmental and tribal claims exceeds $1.775 billion. The $2.8 billion civil figure and the $3.544 billion fine are thus claim amounts against the estates, grouped as 'DOJ Unsecured Claims', rather than payments; the cash payment this part of the order specifies is the $225 million for the forfeiture. ^{1 2 3 4}

analysisThe Information alleges that Purdue Pharma L.P. sent its hundreds of sales representatives repeatedly to the most prolific opioid prescribers, listed as 'Super Core' and 'Core' prescribers, in part because it knew that the top 2 percent of opioid prescribers wrote close to 80 percent of OxyContin prescriptions nationwide, and kept listing them after its own analyses showed that the highest prescribers were the most likely to be diverting; representatives were also told to give prescribers savings cards that reduced patients' costs. It states that the company's anti-diversion procedure, SOP 1.7.1, later the Abuse and Diversion Detection (ADD) Program, ran from about November 2002 to April 2018, that staff filed 'Reports of Concern', and that prescribers it decided to stop detailing were placed on a 'Region Zero' list; the United States' 2020 proof of claim likewise dates the program from about 2002 to 2018. It alleges that from 2007 to 2018 the company reviewed about 6,500 prescribers and pharmacies and in over a hundred instances kept promoting to a prescriber despite information indicating diversion; that it earned over one hundred million dollars a year from Region Zero prescribers, with executives at times giving the board of directors per-prescriber figures (the board of the general partner, Purdue Pharma Inc., managed the partnership, and no director is named); that it honoured savings cards linked to hundreds of those prescribers; and that while its anti-diversion efforts were failing it touted them to the DEA: a senior member of its legal department and a senior member of its compliance team met DEA staff on about 12 April 2011 and explained that the ADD Program was designed to stop promotion to prescribers engaged in abuse or diversion, and company representatives told DEA staff in October and December 2011 that the program was effective in combatting illegal diversion. Like the rest of the Information, this is the prosecution's account: DOJ summarised the conduct Purdue Pharma L.P. admitted as running from May 2007 to at least March 2017 and involving more than 100 providers, the agreed statement it stipulated to (Schedule A) is not in the retained record, and beyond the guilty plea and its chairman's acceptance of responsibility no answer to these details was found. The sentence of 28 April 2026 on the three counts was a $3.544 billion fine and $2 billion forfeiture, against which DOJ will credit up to $1.775 billion for value conferred on state, local and tribal governments if Purdue ceases to operate in its current form and emerges as a public benefit company or similar entity; the plan confirmed on 18 November 2025 carries both as DOJ claims and finds that value above $1.775 billion was conferred. ^{1 2 3 4 5 6}

analysisCount One further alleges that Purdue Pharma L.P. and certain Purdue entities applied each year for DEA authorisation to manufacture within its quotas and that, to support the requests, Purdue Pharma L.P. supplied prescription data presented as legitimate sales without telling the DEA that prescriptions worth over $1.17 billion between May 2007 and February 2018 were written by Region Zero prescribers it knew or believed to be diverting; the listed submissions were made in the names of Purdue Pharmaceuticals L.P. from February 2008 to May 2018 and Purdue Pharma Manufacturing L.P. in July 2018, neither of which was charged. It also alleges that the company kept detailing and supplying savings cards to prescribers it knew were writing invalid prescriptions, intending its products to be dispensed on them, and that about 96 percent of those products were paid for by health care benefit programs. Reporting misleading prescription data to the DEA to boost quotas is part of the conduct DOJ said Purdue admitted; the $1.17 billion figure and the list of submissions are the Information's. Like the rest of the Information, this is the prosecution's account: DOJ summarised the conduct Purdue Pharma L.P. admitted as running from May 2007 to at least March 2017 and involving more than 100 providers, the agreed statement it stipulated to (Schedule A) is not in the retained record, and beyond the guilty plea and its chairman's acceptance of responsibility no answer to these details was found. The sentence of 28 April 2026 on the three counts was a $3.544 billion fine and $2 billion forfeiture, against which DOJ will credit up to $1.775 billion for value conferred on state, local and tribal governments if Purdue ceases to operate in its current form and emerges as a public benefit company or similar entity; the plan confirmed on 18 November 2025 carries both as DOJ claims and finds that value above $1.775 billion was conferred. ^{1 2 3 4 5}

analysisThe Information illustrates Count One with prescribers identified only by number. Prescriber-1, a 'Super Core' prescriber in Nevada, was visited at least 422 times between January 2007 and February 2018 and generated over $6.7 million in gross proceeds for the company, which kept marketing after a representative reported in October 2009 a pharmacist's complaint that the prescriber's patients were selling their prescriptions. For Prescriber-2, in New York, a senior ADD Program employee recommended on about 24 November 2014 that visits stop and that the prescriber be referred to the DEA, but the program reversed course hours later after a group 'consultation'; from November 2014 until the prescriber's indictment in June 2017 the company made about 34 visits and earned about $834,402, without any referral. Prescriber-3, in Alabama, who wrote the most OxyContin prescriptions in the country in about 2010–2013, was visited at least 214 times from 2007 to March 2013 and generated over $24 million; after a report in December 2011 that the prescriber was under investigation the company kept calling until the licence was surrendered in March 2013, earning over $7 million in that period without a referral. Prescriber-4, in Michigan, a paid member of the company's speaker program who spoke for it about 21 times in 2012 and 2013, was visited at least 325 times between 2007 and May 2014, generating about $16,952,962 in gross proceeds, and the company told its representatives on about 26 March 2012 to keep calling after a report that the office had been raided by law enforcement. Like the rest of the Information, this is the prosecution's account: DOJ summarised the conduct Purdue Pharma L.P. admitted as running from May 2007 to at least March 2017 and involving more than 100 providers, the agreed statement it stipulated to (Schedule A) is not in the retained record, and beyond the guilty plea and its chairman's acceptance of responsibility no answer to these details was found. The sentence of 28 April 2026 on the three counts was a $3.544 billion fine and $2 billion forfeiture, against which DOJ will credit up to $1.775 billion for value conferred on state, local and tribal governments if Purdue ceases to operate in its current form and emerges as a public benefit company or similar entity; the plan confirmed on 18 November 2025 carries both as DOJ claims and finds that value above $1.775 billion was conferred. ^{1 2 3 4 5}

analysisThree further examples run over longer periods. From February 2004, when the company first knew or had good reason to believe that Prescriber-6, in Ohio, was diverting, until it disbanded its opioid sales force in February 2018, it made about 226 visits, redeemed about 420 savings cards and earned over $47.1 million in gross proceeds, having told its representatives on about 25 March 2015 to resume calling. From December 2002, when it first knew or had good reason to believe that Prescriber-9, in Nevada, was diverting, until it stopped redeeming savings cards linked to that prescriber in March 2017, it made over 438 visits, redeemed about 884 cards and earned over $15.3 million; the Information's summary paragraph refers to the cards as linked to 'Prescriber-8', apparently a slip for Prescriber-9. Prescriber-10, owner of a multi-prescriber pain clinic in New York and among the nation's top OxyContin prescribers from 2007 to 2014 with up to 12,961 prescriptions a year, was visited about 227 times between November 2003, when the company first knew or had good reason to believe the prescriber was diverting, and February 2016, with about 232 cards redeemed and over $25.8 million earned, and between January 2007 and February 2016 the company never referred the prescriber to the DEA or any other agency. Like the rest of the Information, this is the prosecution's account: DOJ summarised the conduct Purdue Pharma L.P. admitted as running from May 2007 to at least March 2017 and involving more than 100 providers, the agreed statement it stipulated to (Schedule A) is not in the retained record, and beyond the guilty plea and its chairman's acceptance of responsibility no answer to these details was found. The sentence of 28 April 2026 on the three counts was a $3.544 billion fine and $2 billion forfeiture, against which DOJ will credit up to $1.775 billion for value conferred on state, local and tribal governments if Purdue ceases to operate in its current form and emerges as a public benefit company or similar entity; the plan confirmed on 18 November 2025 carries both as DOJ claims and finds that value above $1.775 billion was conferred. ^{1 2 3 4 5}

analysisCount Two alleges that from about June 2009 through 2016 Purdue Pharma L.P. paid Prescriber-11 at least $476,000 in fees, items and reimbursements as kickbacks to induce prescriptions, during which Medicare paid over $7 million for Prescriber-11's OxyContin prescriptions; that it gave Prescriber-11 about 85 paid speaking engagements although it knew Prescriber-11 was an ineffective speaker, Prescriber-11 writing the most Medicare-reimbursed OxyContin prescriptions in the United States from about 2010 to 2018; and that from about March 2011 through 2018 it paid Prescriber-12 at least $120,000 as kickbacks. DOJ summarised the admitted kickback conduct as payments to two doctors through the speaker program between June 2009 and March 2017; the agreed statement is not in the retained record, and beyond the plea and its chairman's acceptance of responsibility no answer to these details was found. The sentence of 28 April 2026 on the three counts was a $3.544 billion fine and $2 billion forfeiture, against which DOJ will credit up to $1.775 billion for value conferred on state, local and tribal governments if Purdue ceases to operate in its current form and emerges as a public benefit company or similar entity; the plan confirmed on 18 November 2025 carries both as DOJ claims and finds that value above $1.775 billion was conferred. ^{1 2 3 4 5}

analysisCount Three concerns Practice Fusion, Inc., a Delaware company based in San Francisco that gave healthcare providers a cloud-based electronic health records system generally free of charge and earned money by selling pharmaceutical companies 'sponsorships' of clinical decision support (CDS) alerts; it was not a defendant in this case. The Information alleges that Purdue Pharma L.P. paid Practice Fusion kickbacks so that its software would influence doctors' prescribing of extended-release opioids such as OxyContin, Butrans and Hysingla: the two companies signed a contract for a 'Pain CDS' in about March 2016, Purdue paid about $959,700 from March to November 2016, and the alert ran from about July 2016 to April 2019, triggering in more than 230,000,000 patient visits. It quotes Practice Fusion's own model, built after a 31 March 2015 pitch to Purdue, projecting 2,777 additional users of Purdue's extended-release opioids, $8,458,232 to $11,277,645 in added revenue and a return of 5.8 to 7.8 times the cost, and an email excerpt recording that 'they enjoy an 83% share in the branded ERO space', the speaker not being legible in the retained copy; these are Practice Fusion's internal estimates as quoted by the prosecution, not independent market data. In DOJ's description Purdue admitted paying Practice Fusion from about April to December 2016 in exchange for referring, recommending and arranging for the ordering of those products; beyond the plea and its chairman's acceptance of responsibility no answer to the further details was found. The same sentence of 28 April 2026, a $3.544 billion fine and $2 billion forfeiture, applies, with up to $1.775 billion of the forfeiture credited for value conferred on state, local and tribal governments if Purdue ceases to operate in its current form and emerges as a public benefit company or similar entity; the plan confirmed on 18 November 2025 carries both as DOJ claims and finds that value above $1.775 billion was conferred. ^{1 3 4 5}

analysisIn a civil matter separate from the company's case, the United States alleged that from 2013 to 2018 Dr. Richard Sackler, David Sackler, Mortimer D.A. Sackler, Dr. Kathe Sackler and Jonathan Sackler (the 'Named Sacklers') knowingly caused false claims for OxyContin to be submitted to federal healthcare programs. According to DOJ's announcement of 21 October 2020, the settlement resolves allegations that in 2012 they knew the legitimate market for Purdue's opioids had contracted, asked Purdue executives to recapture lost sales, and then approved a 2013 marketing program called 'Evolve to Excellence' that intensified sales calls on extreme, high-volume OxyContin prescribers, and allegations that from about 2008 to 2018, at their request, Purdue transferred assets into Sackler family holding companies and trusts to hinder future creditors. The Named Sacklers expressly deny those allegations, the agreement states that it is not an admission of liability, and the District Court recorded that the Sacklers vehemently deny that any of the transfers were fraudulent conveyances; DOJ stated that there has been no determination of liability in the civil matters. The claims were settled for $225 million plus interest, which the debtors' Disclosure Statement of July 2025 records as already paid directly to the DOJ outside the plan. The federal criminal case named only Purdue Pharma L.P., and DOJ's October 2020 announcement stated that the resolutions gave no individual, family members included, a criminal release. In Harrington v. Purdue Pharma L.P., decided on 27 June 2024, Justice Kavanaugh's dissent stated that the U.S. Government had not brought criminal charges against any of the Sacklers individually and that no State had done so either; that statement speaks as of June 2024 and in the context of the opioid litigation and Purdue's bankruptcy. ^{1 2 3 4 5 6}

analysisThe agreement was made between the United States, acting through DOJ and on behalf of HHS-OIG, the Defense Health Agency, the Office of Personnel Management and the Indian Health Service, and Dr. Richard Sackler, David Sackler, Mortimer D.A. Sackler, Kathe Sackler and the Estate of Jonathan Sackler, described as beneficiaries of trusts that indirectly own Purdue Pharma L.P.; they agreed to pay or cause to be paid $225,000,000 plus 0.75% interest from 5 November 2020 once the Bankruptcy Court confirmed that the payment was not prohibited. It is a personal civil settlement of five family members, one through his estate, separate from the company's plea and civil settlement, and contains no admission of liability. Conditioned on full payment, it releases the Named Sacklers, family members, family trusts and their trustees and protectors, the Purdue parent entities and the independent associated companies from specified civil and administrative monetary claims, but it reserves any criminal liability, preserves HHS-OIG's power to seek exclusion and releases no claim the debtors' estates could bring, including fraudulent-transfer claims against current or former owners and directors; DOJ added that it did not resolve claims states may have against Purdue or family members. As noted above, the debtors' Disclosure Statement of July 2025 records the $225 million as already paid directly to the DOJ, outside the plan. ^{2 4 1}